ir.telomirpharma.com Open in urlscan Pro
3.70.141.173  Public Scan

Form analysis
1 forms found in the DOM

GET https://telomirpharma.com

<form role="search" method="get" class="et-search-form" action="https://telomirpharma.com">
  <label for="s" class="sr-only">Search</label>
  <input id="s" type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:">
</form>

Text Content

Hi! Could we please enable some additional services for Analytics, Marketing &
Strictly Necessary? You can always change or withdraw your consent later.

Manage cookie settings...
I decline optional cookiesI accept all cookies
Skip to main content Skip to section navigation Skip to footer
 * TELOMIR 1
 * THE SCIENCE
 * ABOUT US
   * MANAGEMENT
   * BOARD OF DIRECTORS
   * ADVISORS
 * NEWS & MEDIA
 * INVESTORS
 * CONTACT US
 * 


Select Page Mobile Menu
 * TELOMIR 1
 * THE SCIENCE
 * ABOUT US
   * MANAGEMENT
   * BOARD OF DIRECTORS
   * ADVISORS
 * NEWS & MEDIA
 * INVESTORS
 * CONTACT US
 * 

Search
 * Close


INVESTOR RELATIONS


Investors


INVESTORS

 * Overview
 * News & Events
   * Press Releases
   * IR Calendar
   * Presentations
   * Email Alerts
 * Company Info
   * Company Profile
   * Management
   * Contacts
   * FAQ
 * Financial Info
   * Financial Results
   * Income Statement
   * Balance Sheet
   * Cash Flow
 * Stock Data
   * Quote and Chart
   * Historical Data
 * SEC Filings
   * All SEC Filings
   * Annual Reports
   * Quarterly Reports
   * Section 16 Filings
 * Governance
   * Overview
   * Board of Directors
   * Board Committees
   * Governance Documents
   * Board Diversity


LATEST NEWS

Apr 2, 2024 8:30 am EDT


TELOMIR PHARMACEUTICALS’ ANTI-AGING EXPERT AND NYT BESTSELLING AUTHOR MICHAEL F.
ROIZEN, MD, TO PRESENT PROMISING PRE-CLINICAL DATA FOR AGE-REVERSAL DRUG
TELOMIR-1 AT THE NATIONAL PRESS CLUB IN WASHINGTON, DC, ON APRIL 15, 2024

View Latest Press Release View All News
Mar 29, 2024 4:44 pm EDT


UPDATE – TELOMIR PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ARGENTA TO STUDY
OSTEOARTHRITIS IN CANINES

View Press Release
Mar 26, 2024 8:30 am EDT


TELOMIR PHARMACEUTICALS ANNOUNCES COLLABORATION WITH ARGENTA TO STUDY
OSTEOARTHRITIS IN CANINES

View Press Release
Mar 22, 2024 8:30 am EDT


TELOMIR PHARMACEUTICALS RELEASES NEW PRE-CLINICAL DATA FOR TELOMIR-1 TO BE
PRESENTED AT THE GLOBAL LONGEVITY FEDERATION CONFERENCE IN LAS VEGAS ON MARCH
26TH

View Press Release


LATEST PRESENTATION

Investor Presentation March 2024

View Recent Presentation View All Presentations


LATEST EVENT

Mar 25 – Mar 26, 2024

Global Longevity Federation

View All Events


LATEST FINANCIAL RESULTS


FY 2023

Fiscal Year Ended Dec 31, 2023

10-K
HTML PDF
XBRL
ZIP


LATEST ANNUAL FILING

For Fiscal Year Ending Dec 31, 2023


REPORT LINKS

ANNUAL REPORT DOCUMENT LINKS

View 10-K


EMAIL ALERTS

Sign up today and receive company updates straight to your inbox.

Sign Up Today


COMPANY OVERVIEW

At Telomir Pharmaceuticals, we are committed to developing breakthrough science
to address the root causes of difficult to treat diseases. By partnering with
the brightest minds in science and healthcare, we have the potential to discover
and develop ground-breaking treatments to bring about better health for patients
and change the future of medicine.

View Management Team View Board of Directors


STOCK SNAPSHOT

Apr 2, 2024 3:57 pm ET


MARKET/SYMBOL

Nasdaq: TELO


PRICE

5.495


CHANGE

0.035 (0.64%)


VOLUME

27.97k


DAY RANGE

5.052 - 5.7145


52 WEEK RANGE

4.76 - 20.72


IR CONTACTS


HEADQUARTERS

Telomir Pharmaceuticals, Inc.
855 Wolfe St.
Ste 601.1
Baltimore, MD 21205
United States
T: 813-864-2558
telomir@kcsa.com


INVESTOR RELATIONS

KCSA
Phil Carlson
261 Madison Avenue, 9th Fl.
New York, NY 10016
T: 212-896-1233
telomir@kcsa.com



TRANSFER AGENT

Equiniti
6201 15th Avenue
Brooklyn, NY 11219
T: US 800-401-1957
T: Canada/US Virgin Islands 800-468-9716
T: Other International Access Codes
susan.silber@equiniti.com


 * Accessibility Statement
 * Email Alerts
 * Company Profile
 * Contacts
 * RSS News Feed
 * Sitemap

Contact Us
 * Follow
 * Follow
 * Follow

 * TELOMIR 1
 * THE SCIENCE
 * ABOUT US
   * MANAGEMENT
   * BOARD OF DIRECTORS
   * ADVISORS
 * NEWS & MEDIA
 * INVESTORS
 * CONTACT US

 * TELOMIR 1
 * THE SCIENCE
 * ABOUT US
   * MANAGEMENT
   * BOARD OF DIRECTORS
   * ADVISORS
 * NEWS & MEDIA
 * INVESTORS
 * CONTACT US


 * ADA COMPLIANCE
 * TERMS & CONDITIONS
 * PRIVACY POLICY

 * ADA COMPLIANCE
 * TERMS & CONDITIONS
 * PRIVACY POLICY

©2024 Telomir Pharmaceutical. All Rights Reserved. This site is not intended to
provide medical advice or to suggest that any product mentioned is safe or
efficacious for any disease or condition.

Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless
otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End
of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.